IN2012DN03807A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03807A
IN2012DN03807A IN3807DEN2012A IN2012DN03807A IN 2012DN03807 A IN2012DN03807 A IN 2012DN03807A IN 3807DEN2012 A IN3807DEN2012 A IN 3807DEN2012A IN 2012DN03807 A IN2012DN03807 A IN 2012DN03807A
Authority
IN
India
Prior art keywords
methods
cognitive function
dinaline
impairments
metabolite
Prior art date
Application number
Other languages
English (en)
Inventor
Li-Huei Tsai
Ji-Song Guan
Stephen J Haggarty
Edward Holson
Florence Wagner
Johannes Graeff
Original Assignee
Massachusetts Inst Technology
Gen Hospital Corp
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Gen Hospital Corp, Broad Inst Inc filed Critical Massachusetts Inst Technology
Publication of IN2012DN03807A publication Critical patent/IN2012DN03807A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3807DEN2012 2009-10-30 2010-10-29 IN2012DN03807A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25692709P 2009-10-30 2009-10-30
US26546809P 2009-12-01 2009-12-01
PCT/US2010/054872 WO2011053876A1 (en) 2009-10-30 2010-10-29 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders

Publications (1)

Publication Number Publication Date
IN2012DN03807A true IN2012DN03807A (ru) 2015-08-28

Family

ID=43922604

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3807DEN2012 IN2012DN03807A (ru) 2009-10-30 2010-10-29

Country Status (9)

Country Link
US (2) US8563615B2 (ru)
EP (1) EP2493298A4 (ru)
JP (1) JP2013509441A (ru)
CN (1) CN102834002A (ru)
AU (1) AU2010313255B2 (ru)
CA (1) CA2779497A1 (ru)
IN (1) IN2012DN03807A (ru)
NZ (1) NZ599757A (ru)
WO (1) WO2011053876A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
AU2010313255B2 (en) 2009-10-30 2015-04-30 Massachusetts Institute Of Technology The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8729130B2 (en) 2011-07-01 2014-05-20 The Broad Institute, Inc. Methods of using novel solid forms of tacedinaline
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
US9115053B2 (en) 2011-07-22 2015-08-25 Massachusetts Institute Of Technology Activators of class I histone deacetlyases (HDACS) and uses thereof
EP2877444B1 (en) * 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US20150219673A1 (en) * 2012-09-04 2015-08-06 Massachusetts Institute Of Technology The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
WO2023034440A1 (en) * 2021-09-01 2023-03-09 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
EP1212357B1 (en) 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US20060148743A1 (en) 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20050227300A1 (en) 2001-12-07 2005-10-13 Atadja Peter W Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
CA2473505A1 (en) 2002-02-07 2003-08-14 Ellen M. Leahy Novel bicyclic hydroxamates as inhibitors of histone deacetylase
JP2006505241A (ja) 2002-02-08 2006-02-16 ノバルティス アクチエンゲゼルシャフト Hdac阻害活性を有する化合物のスクリーニング法
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003083067A2 (en) 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
KR20050074487A (ko) 2002-10-17 2005-07-18 메틸진, 인크. 히스톤 데아세틸라아제의 억제제
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
EP1735319B1 (en) 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
JP2007533745A (ja) * 2004-04-20 2007-11-22 アールエヌディー・ファーマシューティカルズ 脂溶性のシリコン置換シクロオキシゲナーゼ−2選択的非ステロイド性抗炎症薬及び誘導体の医薬組成物及び使用方法
DK1591109T3 (da) * 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US20060008517A1 (en) 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
EP1817020A4 (en) 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc INHIBITORS OF HISTONATE ACETYLASE
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20070015183A1 (en) 2005-06-03 2007-01-18 The General Hospital Corporation Biomarkers for huntington's disease
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009507081A (ja) 2005-09-07 2009-02-19 ブレインセルス,インコーポレイティド HDac阻害による神経発生の調整
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
JP2009514859A (ja) 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド 置換ニコチンアミド化合物
US7670817B2 (en) * 2005-11-08 2010-03-02 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
ES2452820T3 (es) 2006-04-07 2014-04-02 Methylgene, Inc. Derivados de benzamida como inhibidores de histona desacetilasa
EP2013196B1 (en) 2006-04-26 2015-09-16 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
CA2651681A1 (en) 2006-05-18 2007-11-29 Merck & Co., Inc. Aryl-fused spirocyclic compounds
WO2008008472A2 (en) 2006-07-13 2008-01-17 President And Fellows Of Harvard College Methods and compositions for modulating synapse formation
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US20110009475A1 (en) 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
CN102159203A (zh) 2008-07-23 2011-08-17 麻省理工学院 组蛋白脱乙酰酶1(hdac1)的活化防范dna损伤和增加神经元存活
US20120101147A1 (en) 2008-12-03 2012-04-26 The General Hospital Corporation D/B/A Massachusetts General Hospital Inhibition of hdac2 to promote memory
US9265764B2 (en) 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
AU2010313255B2 (en) 2009-10-30 2015-04-30 Massachusetts Institute Of Technology The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US9115053B2 (en) 2011-07-22 2015-08-25 Massachusetts Institute Of Technology Activators of class I histone deacetlyases (HDACS) and uses thereof

Also Published As

Publication number Publication date
US8563615B2 (en) 2013-10-22
EP2493298A4 (en) 2013-04-10
EP2493298A1 (en) 2012-09-05
WO2011053876A1 (en) 2011-05-05
AU2010313255B2 (en) 2015-04-30
US20120322879A1 (en) 2012-12-20
NZ599757A (en) 2014-08-29
CA2779497A1 (en) 2011-05-05
CN102834002A (zh) 2012-12-19
US8841346B2 (en) 2014-09-23
AU2010313255A1 (en) 2012-05-31
US20110224303A1 (en) 2011-09-15
JP2013509441A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
IN2012DN03807A (ru)
JOP20180102B1 (ar) مركب صيدلاني
IN2014CN02616A (ru)
MX2011007930A (es) Conjugados de insulina cristalina.
WO2013072932A3 (en) Oral care compositions
HK1220631A1 (zh) 用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
AP2012006189A0 (en) 2'-fluoro substituted carbanucleoside analogs for antiviral treatment.
MX2014004862A (es) Formulaciones de polimero acrilico.
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
TW200942530A (en) Pyridine compounds
MY155330A (en) Methods for salt production
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2012016683A3 (en) Oral dosage form of pregabalin
GB2482817A (en) Novel use
EP2794806A4 (en) AZEOTROPÄHNLICHE COMPOSITIONS WITH CIS-1-CHLORO-3,3,3-TRIFLUORPROPEN
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2009011901A3 (en) Methods for promoting wakefulness
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain